Table 2. Crude Event Rates and Cumulative and Adjusted Cumulative Incidence Estimate Rates.
| Treatment cohort | Evaluable patients at time 0a | Time interval, y | Events, No. | Competing risk events, No. | Patients censored, No.b | No. at risk (end of interval) | Cumulative incidence at end of interval (95% CI)c | Adjusted cumulative incidence at end of interval (95% CI)d |
|---|---|---|---|---|---|---|---|---|
| Prostate cancer-specific mortality | ||||||||
| All RP | 2892 | 0-5 | 99 | 194 | 1561 | 1038 | 5.2 (4.3-6.2) | 5.3 (3.9-7.2) |
| 5-10 | 55 | 77 | 666 | 240 | 13.3 (11.7-15.2) | 13.3 (10.7-16.7) | ||
| All EBRT | 1767 | 0-5 | 67 | 151 | 403 | 1146 | 4.0 (3.2-5.0) | 4.6 (3.7-5.8) |
| 5-10 | 66 | 136 | 489 | 455 | 10.3 (8.9-12.1) | 11.7 (9.7-14.2) | ||
| All EBRT+BT | 911 | 0-5 | 24 | 62 | 184 | 641 | 3.6 (2.8-4.6) | 4.1 (3.6-5.4) |
| 5-10 | 34 | 74 | 318 | 215 | 9.3 (7.4-11.7) | 10.3 (8.1-13.1) | ||
| Optimal RP | 1462 | 0-5 | 35 | 101 | 764 | 562 | 3.6 (2.8-4.6) | 3.4 (2.4-4.8) |
| 5-10 | 18 | 45 | 365 | 134 | 9.3 (7.3-11.9) | 8.2 (6.3-10.6) | ||
| Optimal EBRT | 852 | 0-5 | 28 | 53 | 166 | 605 | 3.3 (2.4-4.5) | 3.3 (2.3-4.8) |
| 5-10 | 31 | 63 | 260 | 251 | 8.4 (6.5-11.3) | 8.1 (6.0-10.7) | ||
| Optimal EBRT+BT | 402 | 0-5 | 7 | 19 | 58 | 318 | 2.8 (2.1-3.9) | 3.4 (2.3-5.0) |
| 5-10 | 13 | 37 | 153 | 115 | 7.4 (5.3-10.3) | 8.1 (5.6-11.7) | ||
| Distant metastasis | ||||||||
| All RP | 2929 | 0-5 | 452 | 197 | 1352 | 928 | 20.3 (18.8-22.1) | 18.4 (16.7-20.2) |
| 5-10 | 109 | 72 | 540 | 207 | 32.7 (30.3-35.3) | 30.2 (27.6-33.1) | ||
| All EBRT | 1793 | 0-5 | 176 | 152 | 384 | 1081 | 11.2 (9.8-12.3) | 11.7 (10.1-13.5) |
| 5-10 | 81 | 143 | 435 | 422 | 18.4 (16.5-20.4) | 19.7 (17.3-22.4) | ||
| All EBRT+BT | 973 | 0-5 | 61 | 74 | 172 | 666 | 6.3 (5.2-7.6) | 6.8 (5.4-8.4) |
| 5-10 | 26 | 106 | 302 | 232 | 10.7 (8.8-13.0) | 11.6 (9.5-14.3) | ||
| Optimal RP | 1539 | 0-5 | 163 | 102 | 750 | 524 | 15 (13.3-17.12) | 13.4 (11.7-15.4) |
| 5-10 | 56 | 45 | 309 | 114 | 26.8 (23.7-30.2) | 23.5 (20.3-27.2) | ||
| Optimal EBRT | 863 | 0-5 | 76 | 53 | 158 | 576 | 9.1 (7.5-11.1) | 8.7 (7.1-10.6) |
| 5-10 | 42 | 66 | 234 | 234 | 16.7 (14.3-19.6) | 16.1 (13.4-19.3) | ||
| Optimal EBRT+BT | 447 | 0-5 | 18 | 27 | 55 | 347 | 3.9 (2.5-5.9) | 4.2 (2.8-6.2) |
| 5-10 | 12 | 57 | 149 | 129 | 7.3 (5.3-10.1) | 7.8 (5.5-11.1) | ||
Abbreviations: BT, brachytherapy boost; EBRT, external beam radiotherapy; RP, radical prostatectomy.
Numbers at baseline differ for prostate cancer-specific survival and distant metastasis-free survival because not all patients had known cause-of-death information to compute prostate cancer–specific survival.
Patients were censored if they were lost to follow-up, if they had not experienced the event of interest at last follow-up, or if they experienced an event such that they were no longer at risk for the event of interest.
Unadjusted cumulative incidence estimates were generated Fine and Gray methods for competing risk.
Adjusted cumulative incidence estimates were generated using Fine and Gray methods for competing risk with inverse probability of treatment weights, calculated using propensity scores that were determined using multinomial logistic regression with treatment cohort as the outcome and site-centered age at treatment, natural log of initial prostate-specific antigen level, clinical T stage, and Gleason grade group as pretreatment, prognostic covariates.